Are There Any Specific Considerations for Pediatric Patients?
- Age: Montelukast is approved for use in children as young as 6 months. Zafirlukast is approved for children aged 5 years and older, while zileuton is not typically recommended for pediatric use. - Dosage: The dosage varies based on the child's age and weight, requiring careful calculation by a healthcare provider. - Monitoring: Children on leukotriene modifiers should be monitored for any behavioral changes or side effects, and liver function should be periodically checked if using zileuton.
